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a b s t r a c t
In this study we evaluated the effects of selective Naþ/Ca2þ exchanger (NCX) inhibition by ORM-10103
on the [Ca2þ]i transient (CaT), action potential (AP), and cell viability in isolated canine ventricular
cardiomyocytes exposed to a simulated ischemia/reperfusion protocol performed either alone (modeling
moderate low-ﬂow ischemia) or with simultaneous strophantidine challenge (modeling more severe
low-ﬂow ischemia). CaTs were monitored using a Ca2þ-sensitive ﬂuorescent dye, APs were recorded by
intracellular microelectrodes, and anaerobic shifts in cellular metabolism were veriﬁed via monitoring
native NADH ﬂuorescence. Simulated ischemia increased the NADH ﬂuorescence, reduced the amplitudes
of the AP and CaT and induced membrane depolarization. APs moderately shortened, CaTs prolonged.
Diastolic [Ca2þ]i ([Ca2þ]iD) level increased signiﬁcantly during ischemia and further elevated following
strophantidine application. Reperfusion normalized the NADH level, the amplitude of the AP and
duration of the [Ca2þ]i transient, but only partially restored action potential triangulation and the
amplitude of the CaT. [Ca2þ]iD decreased in untreated, but further increased in strophantidine-treated
cells. 10 mM ORM-10103 signiﬁcantly reduced the ischemic [Ca2þ]i raise in both untreated and
strophantidine-treated cells. During reperfusion ORM-10103 decreased [Ca2þ]i and eliminated its
diastolic elevation in untreated and strophantidine-treated cardiomyocytes. Following the application
of ORM-10103 the detrimental effect of ischemia/reperfusion on cell viability and the reperfusion-
induced increase in AP and CaT variabilities were substantially reduced, but ischemia-induced shifts in
AP morphology were barely inﬂuenced. In conclusion, selective NCX inhibition by ORM-10103 is highly
effective against ischemia/reperfusion induced pathologic alterations in [Ca2þ]i homeostasis, however, it
fails to normalize untoward arrhythmogenic changes in AP morphology.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Cardiac Naþ/Ca2þ exchanger has a pivotal role in removal of
the excess Ca2þ (forward transport mode) entering mainly via
L-type Ca2þ channels during the AP, however it may also con-
tribute to Ca2þ entry (reverse transport mode). Therefore, its
balanced activity is essential in maintaining cardiac [Ca2þ]i home-
ostasis and any abnormal change in its transport activity may
severely impair the contractile function and the electrical activity
of the beating heart.
During hypoxia the raise in [Naþ]i shifts the NCX into its
reverse transport mode. The reduction in [Kþ]i depolarizes the
sarcolemma (Baczko et al., 2003; Tanaka et al., 2002), further
facilitating reverse mode NCX activity and leads to gradual [Ca2þ]i
accumulation. During the early phase of ischemia the major source
of the [Ca2þ]i increase is the leaky SR (Zucchi and Ronca-Testoni,
1997), while during the late phase, [Ca2þ]i accumulation via NCX
is accelerated (Bourdillon and Poole-Wilson, 1981; Haigney et al.,
1992). During reperfusion the secondary [Naþ]i raise further
activates the already high reverse mode transport, generating
[Ca2þ]i overload and subsequently increased SR Ca2þ content.
These alterations often lead to abnormal membrane potential
changes (Volders et al., 2000) enhanced probability of diastolic
Ca2þ releases (Diaz et al., 1997), enhanced arrhythmia propensity
(early and delayed afterdepolarizations) and cellular injury
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(Talukder et al., 2009). During incomplete (low-ﬂow) ischemia/
reperfusion the changes in [Naþ]i and [Ca2þ]i homeostasis are less
dramatic (Wei et al., 2007).
Up to present benzyloxyphenyl derivatives KB-R7943 and
SEA0400 were considered as the best NCX inhibitors. In isolated rat
cardiomyocytes exposed to simulated ischemia KB-R7943 reduced
the [Ca2þ]i overload and delayed the onset of the contracture
(Ladilov et al., 1999). The raise in [Ca2þ]i, induced by the removal
of extracellular Naþ , was blocked by 90% in the presence of
KB-R7943 (Tokuno et al., 2000). In reoxygenated rat cardiomyocytes
hypercontracture and [Ca2þ]i oscillations were signiﬁcantly reduced
in the presence of KB-R7943 (Schafer et al., 2001). Both SEA0400 and
KB-R7943 inhibited the Naþ-dependent Ca2þ uptake in rat cardio-
myocytes. Similar, positive effects of NCX inhibition were reported
from isolated guinea pig papillary muscles and rat hearts (Anderson,
2002; Schafer et al., 2001; Wang et al., 2007). NCX inhibitors were
shown to attenuate myocardial reperfusion injury using in vivo
experimental models (Takahashi et al., 2003). Under normal condi-
tions or during ischemia 1 mM SEA0400 had no apparent effect on AP
conﬁguration, but improved the recovery of action potentials after
reperfusion (Acsai et al., 2007).
Previous data (Inserte et al., 2002; MacDonald and Howlett,
2008; Wei et al., 2007) suggest that inhibition of the reverse mode
NCX activity during ischemia/reperfusion exert effective cardio-
protection by reducing [Ca2þ]i overload and improving myocardial
recovery during reperfusion. However, the inhibitors used in these
studies were not fully selective (Birinyi et al., 2005), consequently
the overall effect of NCX inhibition could not be quantitatively
analyzed. Therefore, the aim of the present study was to evaluate
the cardioprotective effect of a novel, selective NCX inhibitor,
ORM-10103 (Jost et al., 2013) in isolated canine ventricular
cardiomyocytes in conditions of simulated ischemia/reperfusion.
This aim was accomplished by analyzing the primary, simulated
ischemia/reperfusion induced shifts in characteristic variables on
the CaT and AP and evaluating the modulatory effects of selective,
partial NCX inhibition on these shifts. Supplementary experiments
were also performed in order to directly estimate and compare the
survival rate during ischemia and reperfusion of untreated and
ORM-10103 treated cardiomyocytes.
2. Materials and methods
All animal experiments were carried out in compliance with
the Guide for the Care and Use of Laboratory Animals (USA NIH
Publication no. 86-23, revised 1996) and conformed to Directive
2010/63/EU of the European Parliament. Furthermore, all experi-
mental protocols were approved by the Ethical Committee for
Protection of Animals in Research of the University of Szeged,
Hungary (Permit no. I-74-9/2009).
2.1. Isolation of canine left ventricular cardiomyocytes
Canine ventricular cardiomyocytes were isolated from adult
mongrel dogs of either sex weighing 10 to 20 kg. Following
sedation (xylazine, 1 mg/kg, i.v.) the animals were anaesthetized
with 30 mg/kg thiopental and anticoagulated with sodium-
heparin. The proper depth of anesthesia was carefully tested with
pupilla and pain reﬂexes. Following right lateral thoracotomy the
heart was quickly removed and immediately rinsed in oxygenated
modiﬁed Locke's solution containing (in mM): Naþ 140, Kþ 4,
Ca2þ 1.0, Mg2þ 1, Cl 126, HCO3 25 and glucose 11. The pH of
the solution, bubbled with 95% O2 and 5% CO2 at 37 1C, ranged
from 7.35 to 7.45. Excised left ventricular segments were perfused
at 37 1C through the anterior descending coronary artery using
a gravity ﬂow Langendorff apparatus. First, to remove the blood
the heart was washed for 5 min with isolation solution containing
1 mM Ca2þ , then the perfusate was switched to a Ca2þ-free
solution containing (in mM) 135 NaCl, 4.7 KCl, 1.2 KH2PO4,
1.2 MgSO4, 10 HEPES, 10 glucose, 20 taurine, 4.4 NaHCO3, and 5
Na-Pyruvate (pH 7.2 with NaOH). 10 min later, 75 μM CaCl2 and
150 U/ml collagenase (Worthington Type II), and 15 min later
0.35 U/ml protease (Sigma Type XIV) was added to the perfusate.
Cell dissociation lasted for 30–40 min. At the end of this isolation
process the tissue was minced and gently agitated. The myocytes
were harvested and stored in the isolation solution containing
1 mM Ca2þ at room temperature for the same day or at 4 1C for
next day recordings. Following restoration of the external [Ca2þ]
at least 60% of the cardiomyocytes were rod-shaped showing clear
striation. During measurements the cells were perfused with
Tyrode solution. The Tyrode solution contained (in mM): 144
NaCl, 0.4 NaH2PO4, 4 KCl, 0.53 MgSO4, 1.8 CaCl2, 5.5 glucose and
5 HEPES. The pH was set to 7.4 with NaOH. All measurements were
performed at 37 1C.
2.2. Determination of cell viability
Freshly isolated, unloaded cardiomyocytes, subjected to the
ischemia/reperfusion protocol were visually assessed, classiﬁed
and counted in randomly selected microscopic ﬁelds (Olympus IX
71 inverted ﬂuorescence microscope; 20 objective). A represen-
tative, circular region of the microscopic ﬁeld (region of interest;
ROI), containing predominantly contracting cells, was used for
analysis. Still images of the ROI were periodically captured by an
Olympus digital photo camera (C-7070). In order to safely distin-
guish living and dead cells, instead of using vital dyes, we followed
another, similarly effective classiﬁcation, utilizing characteristic
morphological variables, i.e. the shape and visibility of striation of
the cells (Maddaford et al., 1999). Cardiomyocytes in the ROI were
divided into two classes: Class A: cells with normal (not signiﬁ-
cantly shortened) shape, intact border and visible striation; Class
B: cells dead or at the verge of death, in severe contracture,
parallel striation cannot be observed. The cells were stimulated
(1 Hz) throughout the experiment. The number of surviving and
dead cells was determined several times (at 0th,1.5th,3rd,
4rth,10th,15th,23rd,24rth,26th,30th,32nd min) during the ische-
mia/reperfusion protocol.
2.3. Validation of the level of simulated ischemia via NADH
measurements
Parallel to the shift from aerobic to anaerobic metabolism
a substantial fraction of the intramitochondrial NADþ content is
gradually reduced. Since only the reduced form, NADH is ﬂuor-
escent, a raise in [NADH]m is considered as a direct indicator of
ischemia. In this set of experiments NADH was excited at 360 nm,
while the native cellular ﬂuorescence was monitored at 450 nm.
The relative magnitude of the momentary ﬂuorescent shift com-
pared to the maximal raise achieved following the application of
10 mM NaCN has been used to characterize the level of ischemia.
Therefore, cardiomyocytes were stimulated at 1 Hz and the simu-
lated ischemia/reperfusion protocol (i.e. 3–5 min normoxic con-
trol, 20 min simulated ischemia and 10 min reperfusion – see
details below) was used. At the end of the protocol the cells were
exposed to 10 mM cyanide, which quickly induced maximal NADþ
reduction.
2.4. Monitoring [Ca2þ]i transients in single ventricular
cardiomyocytes
[Ca2þ]i transients were monitored using a Ca2þ-sensitive
ﬂuorescent dye, Fluo 4. Isolated cardiomyocytes were loaded with
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6 mM Fluo 4-AM (AM is the membrane permeable acetoxymethyl
ester conjugated form of the dye) for 15 min at room temperature
in dark. Loaded cells were mounted in a low volume imaging
chamber (RC47FSLP, Warner Instruments) and ﬁeld-stimulated at
a rate of 1 Hz, while continuously superfused with normal (during
control and reperfusion periods) or “simulated ischemic” Tyrode
solution. Fluorescence measurements were performed on the
stage of an Olympus IX 71 inverted ﬂuorescence microscope. The
dye was excited at 480 nm and the emitted ﬂuorescence was
detected at 535 nm. Optical signals were sampled at 1 kHz and
recorded by a photon counting photomultiplier module (Hama-
matsu, model H7828). Data acquisition and analysis were per-
formed using a CAIRN Optoscan System. Alterations in [Ca2þ]i
were characterized by the corresponding changes in background
corrected ﬂuorescence normalized to the control state (F/F0).
Amplitudes of the [Ca2þ]i transients were calculated as differences
between systolic and diastolic values. Diastolic [Ca2þ]i levels were
determined immediately before the onset of the stimulus. Systolic
[Ca2þ]i was determined at the peak of the corresponding transi-
ent. [Ca2þ]i changes were expressed as ﬂuorescence measured
over basal unstimulated ﬂuorescence (F/F0). Background ﬂuores-
cence levels were recorded for a few times during each experi-
ment and were used to correct raw ﬂuorescence data.
2.5. Recording of single cell action potentials
Single cell APs were recorded using conventional sharp micro-
electrodes. Selected cardiomyocytes were impaled with high-
resistance (20–40 MΏ) electrodes ﬁlled with 3 M KCl. APs were
recorded with an Axoclamp 900 A ampliﬁer (Axon Instruments)
and were analyzed using the Clampﬁt 10.0 software (Molecular
Devices Corporation). Action potential parameters, such as ampli-
tude, plateau level, duration (both APD25 and APD90) and triangu-
lation (APD90–APD25) of the AP, and the resting membrane
potential were determined.
2.6. Introducing simulated ischemia
As in similar studies, simulated ischemia was introduced using
a low pH, low pO2, high Kþ , glucose free, high lactate perfusion
solution (composition (in mM): 123 NaCl, 6 NaHCO3, 0.9 NaH2PO4,
8 KCl, 0.5 MgSO4, 2.5 CaCl2 and 20 lactate) (Louch et al., 2002). The
cells were ﬁrst perfused with normal Tyrode solution (normoxia:
3 min), then with simulated ischemic solution (ischemia: 20 min),
and ﬁnally again with normal Tyrode solution (reperfusion:
10 min). During the ischemic period an oxygen-free gas combina-
tion (95% N2þ5% CO2) was layered over the solution. Each cell was
exposed to the ischemia/reperfusion cycle only once. The oxygen
level in the ischemic solution was decreased to a very low level by
heavily gassing the solution with the anoxic gas mixture. The pO2
level in the solution was periodically checked using a clinical blood
gas analyzer (Radiometer ABL 505). The pO2 level was approxi-
mately 180 mmHg in normal Tyrode. This rapidly declined to
about 32 mmHg (determined in the chamber) in the ischemic
solution, which represents a reasonably high level of hypoxia.
2.7. Experimental protocols
In the present study 4 principal sets of experiments were
performed: cell viability measurements, NADH measurements,
[Ca2þ]i transient measurements and AP measurements. In order
to reach maximal, but still selective inhibition of the exchanger,
ORM-10103 has been used in 10 mM dose. At this dose no apparent
effect of the inhibitor on further ion transporters (except a small
inhibition of IKr) could be observed (Jost et al., 2013).
1) Viability measurements: Two subsets of experiments were
performed. The ischemia/reperfusion protocols were identical
to the corresponding subsets of the AP measurements (native,
untreated and ORM-10103 treated cardiomyocytes). Since
under normoxic conditions cell survival was usually close to
100% for at least an hour, no separate time control ( TC)
measurements were performed.
2) NADH measurements: Since NADH is inherently ﬂuorescent, no
cells in this group had to be loaded with external dye.
Cardiomyocytes in the ﬁrst subgroup were utilized as time
control and were superfused with oxygenated Tyrode solution
throughout the experiment; no simulated ischemia was intro-
duced. The second subgroup of cells was subjected to a full
cycle of ischemia/reperfusion (see above).
3) [Ca2þ]i transient measurements: These measurements were
performed in cardiomyocytes loaded with Fluo 4-AM. Five
subsets of experiments were performed. The ﬁrst subset was
used for time control; no ischemia/reperfusion (I/R) cycle was
applied. In the second one (untreated) cells were subjected to
a full cycle of ischemia/reperfusion. In the third one (ORM-10103)
cells were pretreated with 10 mM of ORM-10103, the selective
NCX inhibitor, at the end of the control period but prior to the
ischemia/reperfusion cycle. The fourth and ﬁfth subsets were
similar to the second and third ones, with the exception that in
order to substantially increase the driving force for reverse mode
NCX activity these solutions also contained the Naþ/Kþ-ATP-ase
(NKA) inhibitor strophantidine (1 mM).
4) AP measurements: Three subsets of experiments were per-
formed. The protocols were identical to the corresponding
subsets of the [Ca2þ]i transient measurements (i.e. untreated,
ORM-10103 treated and time control), but these measurements
were performed using unloaded cardiomyocytes.
2.8. Variabilities of APD90,APD25 and the [Ca
2þ]i transient
The beat-to-beat variability of APD90, APD25, and CaT amplitude
were calculated by the analysis of 50 consecutive action potentials
or [Ca2þ]i transients from the steady-state section of the experi-
ment, via using the following formulas:
BVRðADP90Þ ¼ΣðAPD90; iþ1APD90; iÞ=ðnbeatsx√2Þ
BVRðADP25Þ ¼ΣðAPD25; iþ1APD25; iÞ=ðnbeatsx√2Þ
Since the uncorrected CaT amplitude largely depends on non-
speciﬁc variables (cell size, dye concentration and leakage) and
this dependence would also be reﬂected in the variabilities, the
simple formula used to calculate short term APD variabilities may
not be suitable to properly characterize CaT variabilities. Therefore,
we normalized the raw variability data to the mean CaT amplitude
(CaTTC), calculated from the corresponding time control experi-
ments, as follows:
BVRðCaTÞ ¼ΣðCaT amplitude; iþ1CaT amplitude; iÞ=ððnbeatsx√2Þ
 mean CaTTCamplitudeÞ
2.9. Materials
All materials were purchased from Sigma (St. Louis, Mo, USA)
except for Fluo 4-AM (Life Technologies). ORM-10103 was a gift
from Orion Pharma (Espoo, Finland).
2.10. Data processing and statistics
Individual cardiomyocytes—even if selected from the same
isolation—show great variability in size and volume. Consequently,
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at the end of the loading process their ﬂuorescent dye content—
even at identical [Ca2þ]i—showed signiﬁcant variations and this
variability was fully reﬂected by the magnitude of the optical
signals. Therefore, to avoid abnormally high standard deviations
caused solely by the heterogeneity of the dye content, ﬂuorescence
values were normalized to the control period.
In contrast to the “survival” data shown in Fig. 1, all single cell
data presented in Figs. 2–9 were obtained from living cardiomyo-
cytes, surviving the ischemia/reperfusion protocol. Incomplete single
cell measurements were discarded from data analysis. All values
presented are arithmetic means7S.E.M. All data were analyzed
using Students t test for paired or unpaired data, as relevant.
Differences were considered signiﬁcant when P was less than 0.05.
3. Results
3.1. Effect of selective NCX inhibition on cardiomyocyte viability
The results obtained from the “survival” experiments are shown
in Fig. 1. Representative microscope ﬁelds from a pair of experiments
performed on untreated and ORM-10103 treated cardiomyocytes are
shown in panels (A) and (B), respectively. For survival analysis
regions of interest (ROIs, white circles) containing 20 predomi-
nantly intact, contracting cardiomyocytes were selected at the
beginning of the normoxic period (left panels). Based on their
morphological characteristics cells in the ROI were classiﬁed into
two groups: Class A: elongated cells with intact border and clearly
visible striation. Class B: dead cells, or cells on the verge of death
with no visible striation and typically in full contracture. At the end
of the ischemic period most cardiomyocytes in both ROIs seem to be
principally intact (mid panels). At the end of the reperfusion period,
however, a substantial number of the cells was in contracture (right
panels). This is especially true for the untreated group.
Mean values, determined for both groups in the last minute of the
control (normoxic), ischemia and reperfusion periods, are shown in
panel (C). The distribution of cells in the normoxic state was close to
identical in both groups, and the majority of these cells was intact
(78% and 81% in the untreated and ORM-10103 treated groups,
respectively). As noted above, ischemia by itself apparently did not
inﬂuence cell distribution in either group. In contrast, reperfusion
had a detrimental effect on the untreated group: 71% (112 out of 156)
of the cells intact at the end of ischemia died during reperfusion.
Application of 10 mM ORM-10103 had a clearly protective effect on
cell viability; signiﬁcantly less, only 47% (76 out of 161) of the ORM-
treated cells died by the end of the reperfusion period.
Fig. 1. Effect of 10 mM ORM-10103 on cardiomyocyte viability. (A, B) Representative selected microscope ﬁelds from a pair of experiments performed on untreated and
ORM-10103 treated native cardiomyocytes. Still images were periodically captured using a digital photo camera. Classiﬁcation of the cells was based on morphological
variables: Class A: cells with normal, elongated shape, intact border and visible striation; Class B: cells dead or at the verge of death, in severe contracture, without apparent
striation. (C) Mean values prior to (3rd min), during (15th min) and following (26th min) simulated ischemia. The asterisks indicate signiﬁcant (Po0.05) difference between
individual untreated and ORM-10103 treated values.
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3.2. Validation of intracellular ischemia by monitoring NADH levels
The onset and relative depth of intracellular ischemia
were veriﬁed by monitoring ischemia induced shifts in inherent
ﬂuorescence of dye-unloaded (native) cardiomyocytes and com-
paring those to nonspeciﬁc, time dependent ﬂuorescence shifts
developed in nonischemic cells. In order to estimate the depth of
intracellular ischemia NaCN—a well known inhibitor of the mito-
chondrial cytaa3, often used to induce close to maximal short term
reduction in NADþ—was applied immediately following the
reperfusion period. The results of the NADH ﬂuorescence mea-
surements are shown in Fig. 2.
Fig. 2. Effect of simulated ischemia/reperfusion on NADH levels in isolated dye-free cardiomyocytes. In untreated, native cardiomyocytes NADH was excited at 360 nm,
native ﬂuorescence during the ischemia/reperfusion protocol has been monitored at 450 nm (gray circles). Nonspeciﬁc ﬂuorescence shifts, caused by NADH bleaching, were
estimated from normoxic (time control) cardiomyocytes (black circles). At the end of the protocols 10 mM sodium-cyanate (NaCN) was applied to induce maximal NADH
reduction (squares). Asterisks indicate signiﬁcant (Po0.05) difference between individual ischemic and time control values (n¼6).
Fig. 3. Representative [Ca2þ]i transients recorded from untreated normoxic (time control) and ORM-10103 treated normoxic cardiomyocytes. In CaT measurements the
cardiomyocytes were loaded with a Ca2þ-sensitive ﬂuorescent dye, Fluo 4-AM. (A) Time control (normoxic) measurements were performed to enable the estimation of the
rate of nonspeciﬁc ﬂuorescence decay caused by dye leakage/extrusion. This decay factor was used to correct raw data obtained from all ischemia/reperfusion experiments.
(B) In a predominant number of normoxic cardiomyocytes application of 10 mM ORM-10103 did not cause apparent changes in the magnitude, shape and decay kinetics of
the transient, while in a minority of cells some decrease could be observed.
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In cells not exposed to ischemia (time control group) only
a limited, gradual decrease in cellular ﬂuorescence, most likely a
consequence of nonspeciﬁc changes (bleaching), could be
observed (black circles). In contrast, in cells exposed to the
ischemia/reperfusion protocol cellular ﬂuorescence increased sig-
niﬁcantly during the ischemic period (gray circles). When switch-
ing perfusion solutions 30 s was necessary for the new perfusate
to reach the chamber, and about further 1 min to mix and
decrease the oxygen level in the chamber low enough to induce
anaerobic transition. Ischemia-induced NADH shifts were calcu-
lated by correcting raw ﬂuorescence values for nonspeciﬁc
changes (calculated from the time control measurements).
Furthermore, all ﬂuorescence data shown in Fig. 2 were normal-
ized to the level obtained from the same cell at the beginning of
the normoxic period.
In the early phase of ischemia a steep increase in [NADH] could
be observed (8.470.4%; n¼6). During the ischemic cycle the level
of the corrected ﬂuorescence increase was varying, most probably
reﬂecting the minor variations in oxygen levels inside the cham-
ber. During reperfusion [NADH] gradually returned to control
level, even a minimal, insigniﬁcant undershoot could be observed.
Compared to simulated ischemia, the application of cyanate
induced signiﬁcantly larger NADþ reduction (ischemic and time
control cells: 12.272.8% and 15.171.9%, respectively, n¼4). Dur-
ing these measurements pO2 levels were repetitively determined
using a blood gas analyzer (ABL 505, Radiometer, Denmark) in
50 ml samples collected from the central area of the chamber.
While the pO2 level in the chamber was sufﬁciently high during
normoxia (181.777.5 mmHg, n¼25) under ischemic perfusion it
was always lower than 40 mmHg (32.971.6 mmHg, n¼25).
3.3. The effect of selective NCX inhibition on the [Ca2þ]i transient
A set of representative CaT waveforms is shown in Figs. 3–5.
In time control measurements only a small, gradient decrease in
the magnitude and baseline of the transient could be observed
Fig. 4. Changes in major CaT parameters during simulated ischemia/reperfusion and the effect of 10 mM ORM-10103 treatment on these parameters in strophantidine-
untreated cardiomyocytes. (A) Representative raw recordings of CaT from untreated (upper traces) and ORM-treated (lower traces) cells prior to, during and following
simulated ischemia. CaTs shown in this panel were corrected for dye leakage and nonspeciﬁc background, but were not normalized. (B–E) Ischemia/reperfusion induced
shifts in major CaT variables and the effect of 10 mM ORM-10103 on the (B) magnitude, (C) slope and (D) half-relaxation time of the transients. Parameter values were
obtained in the 3rd min (control), 6th, 10th, and 15th min (early, mid and late phase of ischemia), and 26th and 30th min (early and late phase of reperfusion) of the
recordings. (E) The changes in [Ca2þ]iD levels are shown in more details. Since the absolute level of the dye ﬂuorescence depends on the size of the individual cells, as well, as
their actual dye concentration, all experiments were self-controlled and all ﬂuorescence values obtained during ischemia/reperfusion were normalized to the mean of the
control values determined from the same cell for each minute during the normoxic period. (C) Slope values, calculated from the CaTs by ﬁtting a line to the ON slope at its
maximal increase rate (i.e. at the peak of the ﬁrst derivative). Fluorescence data were analyzed using Students t test for paired or unpaired data, as relevant. Hash marks and
asterisks indicate signiﬁcant (Po0.05) difference between individual time control vs. untreated and untreated vs. ORM-treated values, respectively. Since two of the three
graphs depicted in these panels are often in close proximity, the commonly used placement of the signiﬁcance marks (i.e. on top of the corresponding graphs) in these panels
could be misleading. Therefore, both signiﬁcance marks are shown in a separate bar on top of the panel.
A. Kormos et al. / European Journal of Pharmacology 740 (2014) 539–551544
(Fig. 3A). This gradual decrease is predominantly a consequence of
dye leakage/extrusion from the cell. Interestingly, under normoxic
conditions the application of 10 mM ORM-10103 had no apparent
effect on the magnitude or kinetics of the transient (Fig. 3B). During
simulated ischemia in both strophantidine untreated (Fig. 4A) and
treated (Fig. 5A) cells signiﬁcant changes in the magnitude and
kinetics of the CaT could be observed. The traces shown in these
panels were corrected for dye leakage (the rate of dye leakage/
extrusion was approximated from time control recordings) and
nonspeciﬁc background ﬂuorescence (determined at the beginning
and end of the recording, by removing the cell from the optical ﬁeld),
but— in contrast to all other (calculated) panels - were not normal-
ized to the control traces. Compared to the normoxic waveforms (left
traces), application of 10 mM ORM-10103 did not prevent or revert
most of these changes (mid traces), indeed, it induced further
alterations in both the magnitude and kinetics of the transient.
During reperfusion neither groups could completely recover,
whether untreated, or treated with 1 mM strophantidine or 10 mM
ORM-10103 or both (right traces).
Ischemia/reperfusion induced changes in characteristic para-
meters of the CaT in strophantidine-untreated cells are shown in
the panels B–E of Fig. 4. In this and a few other Figs. (Figs. 5 and 8)
two distinct signiﬁcance levels were calculated and presented:
hashmarks (♯) and asterisks (n) indicate signiﬁcant difference
between untreated vs. time control, and ORM-treated vs. untreated
values, respectively. Signiﬁcant changes in the amplitude of the
CaT in untreated compared to time control cells could only be
observed during the early phase of ischemia (0.83670.03 vs.
0.97970.02; n¼14) (B). In contrast, 10 mM ORM-10103 caused
a steady, gradual decrease in the amplitude of the CaT (0.7670.06
vs. 0.3870.05; n¼14), which became signiﬁcant (compared to
ORM-10103 untreated cells) during reperfusion. In the slope of the
transient (C) ischemia induced a gradual, signiﬁcant decrease in
untreated cardiomyocytes compared to time control (0.5570.07
vs. 0.5470.05 n¼14) and ORM treatment had no apparent effect
on this ecrease. On the other side, during reperfusion the slope in
the two groups changed in opposite direction - recovered in
untreated, further decreased in treated cells, the differences
between the two groups became signiﬁcant (0.6770.09 vs.
0.3970.04; n¼14). In untreated cells ischemia also caused
a signiﬁcant increase in the half-relaxation time (RT50) of the
CaT, compared to time control (D). In these cells RT50 recovered
during reperfusion, typically with a moderate undershoot com-
pared to time control. In contrast, treatment with ORM-10103
signiﬁcant decreased RT50 (0.9070.03 vs. 0.7970.03; n¼14)
during late ischemia and reperfusion, compared to untreated cells.
The largest modulatory effect of ORM-10103 treatment could be
observed in [Ca2þ]iD (E). As expected, ischemia induced a
Fig. 5. Changes in major CaT parameters during simulated ischemia/reperfusion and the effect of 10 mM ORM-10103 treatment on these parameters in strophantidine-
treated cardiomyocytes. (A) Representative raw recordings of CaT from untreated (upper traces) and ORM-treated (lower traces) cells prior to, during and following
simulated ischemia. (B–E) Ischemia/reperfusion induced shifts in major CaT variables and the effect of 10 mM ORM-10103 on the (B) magnitude, (C) slope and (D) half-
relaxation time of the transients, and (E) [Ca2þ]iD levels. All calculations and representations were performed as shown in Fig. 4.
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substantial raise in [Ca2þ]iD, which became signiﬁcant by the 2nd
min of ischemia. Upon reperfusion [Ca2þ]iD slowly normalized,
however, during its early phase (6 min) it was still signiﬁcantly
higher than in time control cells (1.0470.03 vs. 0.9270.02;
n¼14). Pretreatment of the cardiomyocytes with 10 mM ORM-
10103 completely eliminated the raise in [Ca2þ]iD and by the end
of the ischemic period it even decreased below time control
(0.7370.08 vs. 0.6470.06; n¼14). During reperfusion [Ca2þ]iD
in these cells was permanently below control.
Ischemia/reperfusion induced changes in characteristic para-
meters of the CaT in strophantidine treated cells are shown in
panels B–E of Fig. 5. In these cells no signiﬁcant changes in the
amplitude of the CaT could be observed during ischemia or
reperfusion (B). Compared to time control, the slope of the CaT
gradually, but signiﬁcantly decreased during both ischemia and
reperfusion (C). ORM-10103 failed to inﬂuence the ischemia
induced fall in the slope of the CaT, but signiﬁcantly limited its
further decrease during reperfusion (0.5570.1 vs. 0.2170.02;
n¼6). In ORM-10103 untreated cells RT50 was close to the time
control during both ischemia and reperfusion (D). In contrast, the
application of 10 mM ORM-10103 induced a signiﬁcant decrease in
this parameter during reperfusion (1.1770.11 vs. 0.8170.06;
n¼6). The already signiﬁcant ischemia-induced elevation in
[Ca2þ]iD, observed in the untreated myocytes, was further sig-
niﬁcantly augmented in strophantidine treated cells (E) and this
marked increase was apparently maintained during the entire
period of reperfusion. Application of 10 mM ORM-10103 comple-
tely eliminated the hugh ischemia induced elevation in [Ca2þ]iD;
indeed, diastolic [Ca2þ]i levels in these cells did not differ
signiﬁcantly from levels measured in normoxic cardiomyocytes
(0.7170.06 vs. 0.657 0.06; n¼6).
The beneﬁcial effect of ORM-10103 treatment during reperfu-
sion became even more evident by comparing short term vari-
abilities of the CaT amplitudes. Variabilities calculated from all four
experimental groups for the normoxic, ischemic and reperfusion
periods are shown in Fig. 6. Representative Poincare plots,
obtained in untreated, ORM-10103 treated, strophantidine treated
and strophantidineþORM-10103 treated cells, are shown in panels
A, B, C and D, respectively. Mean data from untreated and ORM-
10103 treated cells are provided in panel (E). As one can conclude
from these diagrams, in untreated cells no apparent ischemia/
reperfusion induced changes in CaT variabilities could be
observed, while ORM 10103 treatment caused a small, rather
insigniﬁcant decrease in both cases (0.01170.002 vs.
0.01070.001 and 0.01270.003 vs. 0.01070.001; n¼6, during
ischemia and reperfusion, respectively). In contrast, as shown in
panel (F), during ischemia strophantidine signiﬁcantly enhanced
the short term variability (0.11370.037 vs. 0.03770.016; n¼6)
which was even further augmented during reperfusion (0.2727
0.055 vs. 0.01870.009; n¼6). This large elevation was, again, fully
eliminated by the application of 10 mM ORM-10103.
3.4. Effect of selective NCX inhibition on AP parameters
Representative AP waveforms are shown in Fig. 7. During
normoxia 10 mM ORM-10103 evoked moderate APD shortening
Fig. 6. The effect of 10 mM ORM-10103 on the amplitude variability of the [Ca2þ]i transient. Variabilities in the amplitude of the CaT were calculated from all four sets of
experiments. Representative examples from untreated, ORM-treated, strophantidine-treated and strophantidineþORM-treated are presented in panels (A), (B), (C) and (D),
respectively. Summarized variabilities for the strophantidine-untreated and treated cardiomyocytes are shown in panels (E) and (F), respectively. The asterisk indicate
signiﬁcant (Po0.05) difference between individual untreated and ORM-treated values.
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without substantially modulating either its amplitude or the
resting membrane potential (A). During simulated ischemia, how-
ever, signiﬁcant changes in the shape and kinetics of the APs
developed and the resting membrane potential was depolarized
(middle trace in panel B). Both parameters were apparently
normalized during reperfusion (right trace in panel B). The AP
shortening effect of 10 mM ORM-10103 observed in normoxic cells
was even more evident during both ischemia and reperfusion
(panel C); however, no additional ORM-10103 induced shifts in AP
could be observed. Indeed, the ORM-treatment failed to substan-
tially reduce the ischemia induced depolarization of the resting
membrane potential.
Ischemia/reperfusion induced alterations in the characteristic
parameters of the AP in untreated and ORM-10103 treated
cardiomyocytes are shown in Fig. 8. Compared to normoxic cells,
ischemia induced a signiﬁcant reduction in the amplitude, a
substantial, but not signiﬁcant decrease in the plateau level of
the AP (A) and (B), and the resting membrane potential became
signiﬁcantly depolarized (C). These parameters were practically
restored during reperfusion. ORM-10103 had no apparent effect on
the magnitude of the ischemia induced shifts, neither on the
recovery of these variables.
In order to characterize major changes in AP kinetics APD25
(D) and APD90 (E) were determined and from these variables AP
triangulation was calculated (F). Ischemia induced a moderate
decrease in APD25 which was normalized during reperfusion.
Compared to the untreated cells substantially larger decrease in
APD25 could be observed in ORM-10103 treated cardiomyocytes,
became signiﬁcant in the late phase of ischemia and did not
recover during reperfusion (0.9070.09 vs. 0.6670.09; n¼9).
Qualitatively similar, but augmented ischemia induced shortening
could be observed in APD90, however, the differences between the
two groups were not signiﬁcant during either ischemia or reperfu-
sion. Compared to the time control cells, ischemia induced a large,
signiﬁcant decrease in AP triangulation in both groups, but again,
the differences between the untreated and ORM-10103 treated
groups were not signiﬁcant (0.6170.07 vs. 0.7670.17; n¼9).
The effect of ORM-10103 treatment during ischemia/reperfu-
sion on the characteristics of the AP was further analyzed by
calculating short term variabilities in APD90 and APD25. Results of
these calculations are shown in Fig. 9. Representative Poincare
plots taken from untreated and ORM-10103 treated cardiomyo-
cytes are presented in panels (A–D). The average values obtained
in the APD90 and APD25 groups are shown in panels (E) and (F),
respectively. Under normoxic conditions APD variabilities were
similar in both groups. Ischemia induced moderate, but insignif-
icant decrease in APD90 variabilities in the untreated group, while
there was no apparent change in the ORM-10103 treated group. In
contrast, APD25 variabilities failed to change in the control group,
but showed a tendency to decrease following ORM-10103
Fig. 7. Representative traces from the action potential measurements. AP measurements were performed in native (dye-unloaded) cells. (A) The effect of 10 mM ORM-10103
on normoxic cardiomyocytes. (B, C) The effect of the simulated ischemia/reperfusion protocol on action potentials recorded ORM-10103-untreated and treated
cardiomyocytes, respectively.
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treatment. During reperfusion the only signiﬁcant change was an
elevation in APD90 variabilities determined in the untreated group.
ORM-10103 treatment eliminated this increase (5.3770.96 vs.
3.4770.69 ms; n¼9).
4. Discussion
Since the Naþ/Ca2þ exchanger plays a crucial role in main-
taining [Ca2þ]i homeostasis, any abnormal shift in its transport
rate or direction exerts a signiﬁcant impact on cardiac contractile
function and electrical activity. Its augmented reverse mode
transport induces [Ca2þ]i overload (e.g. during ischemia/reperfu-
sion) and its increased forward mode activity leads to gradual
[Ca2þ]i loss (e.g. in chronic heart failure) (Allen and Orchard, 1987;
Diaz and Wilson, 2006; Frohlich et al., 2013). In both pathological
conditions partial NCX inhibition may normalize the delicate
balance in intracellular Ca2þ handling, resulting in effective
protection against the progression of the disease. A number of
previous studies provided important information on the conse-
quences of NCX inhibition in healthy and diseased hearts (Inserte
et al., 2002; MacDonald and Howlett, 2008), however, correct
interpretation of these results was seriously hampered by the lack
of selectivity of the used inhibitors. Therefore, in the present study
we evaluated the efﬁcacy of a new, selective NCX inhibitor, ORM-
10103 (Jost et al., 2013) to protect canine ventricular cardiomyo-
cytes during simulated ischemia/reperfusion.
4.1. Cell viability
A most direct way to test the efﬁcacy of the selective NCX
blockade in protecting cardiomyocytes against ischemia/reperfu-
sion injuries is to compare cell survival between untreated and
treated groups (Fig. 1). Instead of using vital dyes, we followed
a similarly effective classiﬁcation, based simply on the shape and
visibility of the striation of the cell (Maddaford et al., 1999). This
form of classiﬁcation may also have some beneﬁts since with
proper experience one is able to reliably dissect crippled, dying
cardiomyocytes from safely surviving cells. The results of these
experiments are straightforward and seem to support the hypothesis
that partial, selective NCX inhibition by ORM-10103 may effectively
protect the cardiomyocytes from severe ischemia/reperfusion
Fig. 8. Changes in major AP parameters during simulated ischemia/reperfusion and the effect of 10 mM ORM-10103 treatment on these parameters in strophantidine-
untreated cardiomyocytes. (A) Amplitude; (B) plateau level; (C) resting membrane potential; (D) APD25; (E) APD90; and (F) triangulation. Parameter values were obtained in
the 3rd min (control), 6th, 10th and 15th min (early, mid and late phase of ischemia), and 26th and 30th min (early and late phase of reperfusion) of the recordings. All data,
except the resting membrane potential values, were normalized to the normoxic (control) period and analyzed using Students t test for paired or unpaired data, as relevant.
Hash marks and asterisks indicate signiﬁcant (po0.05) difference between individual time control vs. untreated and untreated vs. ORM-treated values, respectively. All
signiﬁcance marks are shown in a separate bar on top of the corresponding panel.
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induced injuries. This protection is most probably a direct conse-
quence of the NCX inhibitory effect on the buildup of ischemia-
induced Ca2þi overload leading to contracture and elevated [Ca2þ]iD,
which may severely compromise mitochondrial function (Eisner
et al., 2005). A further contribution of ORM-10103 to cardiomyocyte
survival may be its signiﬁcant stabilizing effect on the CaT and
APD by inhibiting the ischemic increase in their variabilities (Diaz
et al., 2004).
4.2. Level of ischemia
During ischemia compromised oxidative metabolism leads to
marked reduction in mitochondrial NADþ content, reﬂected in
increased cellular ﬂuorescence. Maximal short term raise in
[NADH]m can be well approximated following cyanate application.
The ratio of the magnitudes of ﬂuorescence increase during
ischemia and cyanate treatment is characteristic of the level of
cellular ischemia. In this study the increase in cellular ﬂuorescence
during simulated ischemia was found to be substantially less than
in the presence of cyanate (Fig. 2). Consequently, during this
protocol oxidative metabolism was severely compromised, but
not abolished (Lu et al., 2005). This is not surprising, since the
oxygen level in the chamber was low, but not zero (32.97
1.6 mmHg). Therefore, the simulated ischemia protocol is more
suitable to model the lateral, low-ﬂow zone than the central now-
ﬂow region of the infarcted area. As shown in Fig. 2 NADH
ﬂuorescence was above time control during the ischemic period
and only returned to control level during reperfusion. The appar-
ent gradual ﬂuorescence decrease during the ischemic period was
probably not caused by bleaching only, since the rate of bleaching,
estimated from the time control measurements, was substantially
lower. Indeed, the bleaching-independent component of the
decrease could originate from two principal sources. First, the
pO2 level, reached in the chamber, was probably very close to the
critical pO2 for isolated, active cardiomyocytes; consequently, even
a small shift in chamber pO2 could induce a marked shift in
[NADH]. Another reason may be that in the absence of glucose the
substrate availability during ischemia is decreasing, leading to
partial reoxidation of the mitochondrial NADH pool. At this
moment we have no speciﬁc data to settle this issue; both
explanations are feasible and even may act simultaneously (Eng
et al., 1989).
4.3. [Ca2þ]i transient
In the ORM-untreated cells all well known characteristic con-
sequences of ischemia induced [Ca2þ]i accumulation could be
observed (Fig. 3). Diastolic [Ca2þ]i rose (E) and since the amplitude
of the CaT did not decrease simultaneously (B), systolic [Ca2þ]i
increased, as well. The kinetic parameters CaT were also altered.
The ON slope of the CaT was reduced (C); the half-relaxation time
(RT50) increased (D).
The background of these effects is highly complex: reduced
SERCA activity following ATP depletion leads to decreased SR Ca2þ
content (see the reduced slope and amplitude of the CaT); the
depolarization in resting membrane potential decreases the for-
ward, the high [Naþ]i increases the reverse activity of the NCX. The
latter also facilitates Ca2þ inﬂux, considerably increasing the
Fig. 9. The effect of 10 mM ORM-10103 on APD90 and APD25 variabilities. (A, B) and (C, D) Representative examples for calculated APD90 and APD25 variabilities determined
from untreated and ORM-treated cardiomyocytes, respectively. (E) Summarized APD90 and (F) APD25 variabilities. The asterisk indicates signiﬁcant (Po0.05) difference
between individual untreated and ORM-treated values.
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amount of [Ca2þ]i to be extruded (Bers, 2008; Lee and Allen, 1992).
Reduced SERCA and forward NCX activities should lead to simul-
taneously decreased [Ca2þ]SR and elevated [Ca2þ]i. Upon reperfu-
sion the amplitude and slope of the CaT and (slowly) [Ca2þ]iD were
restored (O’Brien et al., 2008). In contrast, RT50 was shortened. The
acceleration of CaT relaxation during reperfusion may be related to
the fast recovery of the [Kþ]i and subsequent membrane repolar-
ization, which, in turn, may signiﬁcantly increase the efﬁcacy of
the forward NCX activity and facilitate the simultaneous recovery
of the [ATP], subsequently normalizing SERCA activity. The reduc-
tion of RT50 below control level may reﬂect an “overshoot” in Ca2þ
handling during recovery (Talukder et al., 2009).
Application of ORM-10103 had a signiﬁcant impact on ische-
mia/reperfusion induced CaT alterations. The amplitude and slope
of the CaT were gradually decreased, although these differences
only became signiﬁcant during reperfusion. The large decrease
observed in the amplitude of the CaT may support the notion that
during ischemia NCX mediated beat-to-beat Ca2þ inﬂux has an
important role in compensating reduced [Ca2þ]SR. More impor-
tantly, the signiﬁcant ischemia induced raise in [Ca2þ]iD and RT50
were fully blocked by ORM-10103. During reperfusion these
parameters signiﬁcantly further decreased, directly supporting
the hypothesis that the predominant effect of NCX blockade
during ischemia/reperfusion is an effective suppression of the
Naþi -accumulation induced activation of the reverse mode NCX
activity (Wei et al., 2007).
Further support of this conclusion was provided from the
strophantidine experiments. By inhibition of the Naþ/Kþ ATP-ase
strophantidine facilitates Naþi accumulation and consequently, pro-
longs reverse NCX activity. Indeed, ischemia-induced [Ca2þ]iD raise
was approximately doubled, and, in contrast to the untreated cells,
even further increased during reperfusion. ORM-10103 effectively
and completely blocked this raise (Fig. 4E).
Another, highly promising protective effect of ORM-10103 is
shown in Fig. 5. In strophantidine-untreated cardiomyocytes the
variability of CaT was limited, suggesting partially maintained
feedback control of the Ca2þ release on transsarcolemmal Ca2þ
ﬂuxes. In these cells ORM-10103 had no signiﬁcant effect on
variability. In contrast, in strophantidine-treated cardiomyocytes
CaT variabilities during ischemia and especially during reperfusion
were substantially augmented, suggesting that the delicate bal-
ance between the trigger and the feed-back systems was severely
disturbed, leading to large ﬂuctuations in beat-to-beat Ca2þ
release and substantial instability of the Ca-handling (Eisner et
al., 2005). This raise was completely diminished by application of
ORM-10103, whose effect may be contributed to the marked
reduction in [Ca2þ]i. Since elevated CaT variability is often con-
sidered as a sensitive cellular marker for increased arrhythmia
propensity (Tokuno et al., 2000), a reasonable conclusion of these
results is that ORM-10103 is likely to substantially decrease the
incidence of ischemia/reperfusion induced triggered cardiac
arrhythmias.
4.4. AP morphology
Ischemia/reperfusion induced arrhythmias are usually gener-
ated by two interdependent intracellular mechanisms: [Ca2þ]i
overload and sarcolemma depolarization (MacDonald and
Howlett, 2008). [Ca2þ]i overload induces increased leakage of
the [Ca2þ]SR, enhancing the probabilities of diastolic Ca2þ releases
(Wei et al., 2007). The subsequent inward current (mainly via
forward INCX) facilitates the onset of Ca2þ-dependent, potentially
lethal ventricular arrhythmias (Nagy et al., 2004). During ischemia
APD is signiﬁcantly shortened. Membrane depolarization via
elevated Kþi efﬂux reduces the activity of the Naþ and Ca2þ
channels and attenuates Ca2þ extrusion (Lukas and Antzelevitch,
1993). In contrast, augmented [Ca2þ]iD facilitates Ca2þ efﬂux via
forward INCX activity. Finally, ATP depletion-activated IK(ATP) carries
extra repolarizing current. The resulting redistribution of the Ca2þ
and repolarizing Kþ ﬂuxes may substantially contribute to
increased short-term APD90 and CaT variabilities during
reperfusion.
In normoxic cells ORM-10103 treatment induced moderate APD
shortening (Fig. 6A) probably via inhibition of the forward INCX.
Further changes in AP were not observed. During ischemia the
sarcolemma depolarized (Fig. 6B) and the spike potential dimin-
ished, however, both parameters recovered during reperfusion.
ORM-10103 treatment failed to protect the cardiomyocytes against
ischemia-induced AP perturbations (Fig. 6C). The apparent failure
of ORM-10103 to counteract ischemic AP changes is even more
obvious in Fig. 7. The depressed AP amplitude (A) and plateau (B),
increased triangulation (F) and substantial depolarization of the
resting potential (C) were practically uninﬂuenced by ORM-10103
treatment. Indeed, the ischemia-induced APD shortening was even
augmented (D) and (E). The reason for the inefﬁcacy of ORM-
10103 to prevent these arrhythmogenic disturbances in AP may be
complex. Though [Ca2þ]i changes are important modulators of the
AP (Louch et al., 2002), it is more dependent on the balance of the
inward Naþ , Ca2þ and outward Kþ currents. Except for a minimal
decrease in the fast component of the delayed rectiﬁer potassium
current (IKr) neither of these factors are affected by ORM-10103
(Jost et al., 2013). This may be the primary cause for the minimal
sensitivity of the AP to selective NCX blockade.
The only apparent beneﬁcial effect of ORM-10103 on variables
of the action potential was a signiﬁcant reduction in reperfusion-
induced raise of APD90 variabilities (Fig. 8). This may be a
consequence of the increased stability of Ca2þ-handling and is
most probably a consequence of the decreased [Ca2þ]i overload
and reduced [Ca2þ]iD (Wei et al., 2007).
4.5. Limitations
It must be emphasized, that the data shown in Fig. 1 principally
differ from data presented in Figs. 2–9. “Survival” experiments
were performed on full cell populations (the only criterion when
selecting the ROI at the beginning of the experiments was to ﬁnd
an area with predominantly healthy, contracting cells). Our pre-
sent data shown in Fig. 1 and data in the literature (Moens et al.,
2005) clearly demonstrate that a signiﬁcant fraction of the
cardiomyocytes does not survive the simulated ischemia protocol
and dies during the reperfusion period. Since incomplete mea-
surements were discarded from further proccessing, all single cell
(NADH, CaT, AP) data presented were obtained from a limited
cellular pool – i.e. surviving cells.
5. Conclusion
A major conclusion of the present study is that ORM-10103
treatment proved to be highly effective against ischemia/reperfu-
sion induced arrhythmogenic shifts in [Ca2þ]i homeostasis by
limiting the [Ca2þ]i overload and eliminating the ischemia-
induced raise in diastolic [Ca2þ]i. This beneﬁcial effect may
primarily be contributed to the inhibition of the signiﬁcantly
enhanced reverse mode activity of the Naþ/Ca2þ exchanger,
activated by the increased [Naþ]i. Furthermore, ORM-10103 seems
to restore the markedly weakened reperfusion-induced stability of
the [Ca2þ]i transient and signiﬁcantly facilitates the post-
reperfusion survival of the cardiomyocytes. However, in certain
pathological conditions the efﬁcacy of its protective effect may be
hampered by its apparent inability to protect the heart against the
arrhythmogenic disturbances in AP morphology.
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